^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + pelcitoclax (APG-1252) (Bcl2 inhibitor, Bcl-xL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1317MO - Updated study results of pelcitoclax (APG-1252) combined with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC)
Published date:
10/16/2023
Excerpt:
For pts with TP53 and EGFR-positive mutations in EC-3, 13/16 (81.3%) PRs were observed, and the median progression-free survival (range) was 16.39 (8.11-NR) months. Preliminary biomarker data from pts in EC-2 suggested that high BCL-xL expression was associated with antitumor efficacy...Based on these findings, pelcitoclax plus osimertinib is of potential clinical interest to improve outcomes of pts with TP53- and EGFR-mutant NSCLC.
Trial ID:
Source:
Title:
Updated study results of pelcitoclax (APG-1252) in combination with osimertinib in patients (pts) with EGFR-mutant non–small cell lung cancer (NSCLC).
Published date:
05/26/2022
Excerpt:
The median (range) time to response was 1.4 (1.2-7.0) months, and the median duration of response (DOR) was not reached. The DOR rate at 9 months after first response was 71.4% (95% CI 25.8-92.0)….Osimertinib in combination with targeted therapies has been of clinical interest to improve the outcomes of patients with EGFR-mutant NSCLC. Pelcitoclax plus osimertinib was well tolerated and showed comparable efficacy in TKI-naïve pts.
DOI:
10.1200/JCO.2022.40.16_suppl.9116
Trial ID:
